Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 5/20 | 0.33 |
| ▸ | JAK1 | P23458 | 4/20 | 0.32 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.32 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899033 | 0.90 | AAK1 (0.35) | KDRAAK1BTKJAK1ERBB2 | |
| SCHEMBL9898864 | 0.85 | EGFR (0.42) | KDRJAK1ERBB2MKNK1EGFR | |
| SCHEMBL9928300 | 0.84 | KDR (0.34) | KDRERBB2EGFRBRAFTNNI3K | |
| SCHEMBL9928322 | 0.84 | KDR (0.34) | KDRERBB2EGFRBRAFTNNI3K | |
| SCHEMBL9898642 | 0.84 | AAK1 (0.48) | AAK1BTKERBB2EGFR | |
| SCHEMBL9928298 | 0.81 | BRAF (0.36) | KDRAAK1ERBB2EGFRBRAF | |
| SCHEMBL9928319 | 0.80 | TTBK1 (0.42) | KDRERBB2EGFRBRAFTNNI3K | |
| SCHEMBL9943132 | 0.79 | NPFFR1 (0.37) | BTKNPFFR1NPFFR2 | |
| SCHEMBL9943065 | 0.76 | MKNK1 (0.42) | AAK1BTKNPFFR1NPFFR2CDK1 | |
| SCHEMBL9897723 | 0.76 | MKNK1 (0.46) | KDRAAK1BTKMKNK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511276-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | Ube Industries, Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| EP-2511276-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | Ube Industries, Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | KDR 112/4885AAK1 709/4885BTK 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.